ArticleThe Journal of clinical investigation2014
Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.
Article in The Journal of clinical investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 167 citations in OpenAlex.
- Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children.BMC medicine · 2022Trial
- A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.Malaria journal · 2016Trial
- Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.The Journal of infectious diseases · 2015Trial
- Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization.The Journal of infectious diseases · 2014Trial
- Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.PloS one · 2014Trial
- Malaria: a review on its current epidemiological status and management strategies.Malaria journal · 2026Review
- Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.The Journal of experimental medicine · 2025Article
- Virus-like particle vaccines targeting a key epitope in circumsporozoite protein provide sterilizing immunity against malaria.NPJ vaccines · 2025Article
- iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA.NPJ vaccines · 2025Article
- Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention.Nature immunology · 2024Review
- Immature dendritic cell-targeting mRNA vaccine expressing PfCSP enhances protective immune responses againstResearch square · 2024Article
- Ageing of Plasmodium falciparum malaria sporozoites alters their motility, infectivity and reduces immune activation in vitro.Malaria journal · 2024Article
- Ultra-low volume intradermal administration of radiation-attenuated sporozoites with the glycolipid adjuvant 7DW8-5 completely protects mice against malaria.Scientific reports · 2024Article
- A candidate antibody drug for prevention of malaria.Nature medicine · 2024Article
- Malaria Genomics, Vaccine Development, and Microbiome.Pathogens (Basel, Switzerland) · 2023Review
- Affinity-matured homotypic interactions induce spectrum of PfCSP structures that influence protection from malaria infection.Nature communications · 2023Article
- Transport of antibody into the skin is only partially dependent upon the neonatal Fc-receptor.PloS one · 2023Article
- Engineered DNA-encoded monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein confer single dose protection in a murine malaria challenge model.Scientific reports · 2022Article
- Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and may enhance protection of anti-CSP monoclonal antibodies.NPJ vaccines · 2022Article
- Monoclonal antibodies for malaria prevention.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that resulted in 655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 trials with malaria vaccine candidate RTS,S/AS01 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria. RTS,S targets the pre-erythrocytic phase of the disease and induces high antibody titers against the P. falciparum circumsporozoite protein (CSP) and a moderate CD4(+) T cell response. The individual contribution of these adaptive immune responses to protection from infection remains unknown. Here, we found that prophylactic administration of anti-CSP mAbs derived from an RTS,S-vaccinated recipient fully protected mice with humanized livers from i.v.- and mosquito bite–delivered P. falciparum sporozoite challenge. Titers of anti-CSP that conveyed full protection were within the range observed in human RTS,S vaccine recipients. Increasing anti-CSP titers resulted in a dose-dependent reduction of the liver parasite burden. These data indicate that RTS,S-induced antibodies are protective and provide sterilizing immunity against P. falciparum infection when reaching or exceeding a critical plasma concentration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.